Skip to content

Study · Case report or series · n = 1 · 2026

8 results

Symptomatic and Ultrasonographic Improvement in Rheumatoid Arthritis Temporally Associated with Intravenous NAD+ Therapy: A Case Report.

Itani MR, Farhat A, Abou Yehya N, Ghraizi L, Bou Dargham B

ACR open rheumatology1 Sept 2026

PMID42751848 (opens in a new tab)PMCIDPMC13583921 (opens in a new tab)DOI10.1002/acr2.90151 (opens in a new tab)PepBankPUB-42751848
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a woman with rheumatoid arthritis, intravenous NAD+ was temporally associated with rapid pain relief after individual infusions.

    In plain wordsIn a woman with rheumatoid arthritis, NAD+ infusions were linked to rapid pain relief.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreasePain
    Study

    n = 1

    Outcome group
    Pain · Musculoskeletal
    Studied dose
    250 mg · intravenous · four infusions every 2 weeksAs given in this study (human).

    Source sentences

    Summary
    She reported rapid pain relief after individual infusions and subsequent improvement in swelling, morning mobility, function, and analgesic use.
    2 context sentences
    Summary · context
    A 49-year-old woman with a rheumatologist-documented diagnosis of RA had progressive polyarthralgia, intermittent swelling, marked morning stiffness, and baseline hand and wrist ultrasonography showing active synovitis.
    Summary · context
    After approximately 4 months of inconsistently taken methotrexate, discontinued because of adverse effects, she received four intravenous NAD+ infusions for aesthetic and antiaging purposes: 250 mg in 500 mL of 0.9% sodium chloride over approximately 1 hour every 2 weeks.
  2. 02HumanCase report or seriesEfficacy outcome

    In a woman with rheumatoid arthritis, intravenous NAD+ was temporally associated with improved swelling.

    In plain wordsIn a woman with rheumatoid arthritis, NAD+ infusions were linked to improved swelling.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseSwelling
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    250 mg · intravenous · four infusions every 2 weeksAs given in this study (human).

    Source sentences

    Summary
    She reported rapid pain relief after individual infusions and subsequent improvement in swelling, morning mobility, function, and analgesic use.
    2 context sentences
    Summary · context
    A 49-year-old woman with a rheumatologist-documented diagnosis of RA had progressive polyarthralgia, intermittent swelling, marked morning stiffness, and baseline hand and wrist ultrasonography showing active synovitis.
    Summary · context
    After approximately 4 months of inconsistently taken methotrexate, discontinued because of adverse effects, she received four intravenous NAD+ infusions for aesthetic and antiaging purposes: 250 mg in 500 mL of 0.9% sodium chloride over approximately 1 hour every 2 weeks.
  3. 03HumanCase report or seriesEfficacy outcome

    In a woman with rheumatoid arthritis, intravenous NAD+ was temporally associated with improved morning mobility.

    In plain wordsIn a woman with rheumatoid arthritis, NAD+ infusions were linked to improved morning movement.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    IncreaseMorning mobility
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    250 mg · intravenous · four infusions every 2 weeksAs given in this study (human).

    Source sentences

    Summary
    She reported rapid pain relief after individual infusions and subsequent improvement in swelling, morning mobility, function, and analgesic use.
    2 context sentences
    Summary · context
    A 49-year-old woman with a rheumatologist-documented diagnosis of RA had progressive polyarthralgia, intermittent swelling, marked morning stiffness, and baseline hand and wrist ultrasonography showing active synovitis.
    Summary · context
    After approximately 4 months of inconsistently taken methotrexate, discontinued because of adverse effects, she received four intravenous NAD+ infusions for aesthetic and antiaging purposes: 250 mg in 500 mL of 0.9% sodium chloride over approximately 1 hour every 2 weeks.
  4. 04HumanCase report or seriesEfficacy outcome

    In a woman with rheumatoid arthritis, intravenous NAD+ was temporally associated with improved function.

    In plain wordsIn a woman with rheumatoid arthritis, NAD+ infusions were linked to improved function.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    IncreaseFunction
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    250 mg · intravenous · four infusions every 2 weeksAs given in this study (human).

    Source sentences

    Summary
    She reported rapid pain relief after individual infusions and subsequent improvement in swelling, morning mobility, function, and analgesic use.
    2 context sentences
    Summary · context
    A 49-year-old woman with a rheumatologist-documented diagnosis of RA had progressive polyarthralgia, intermittent swelling, marked morning stiffness, and baseline hand and wrist ultrasonography showing active synovitis.
    Summary · context
    After approximately 4 months of inconsistently taken methotrexate, discontinued because of adverse effects, she received four intravenous NAD+ infusions for aesthetic and antiaging purposes: 250 mg in 500 mL of 0.9% sodium chloride over approximately 1 hour every 2 weeks.
  5. 05HumanCase report or seriesEfficacy outcome

    In a woman with rheumatoid arthritis, intravenous NAD+ was temporally associated with improved analgesic use.

    In plain wordsIn a woman with rheumatoid arthritis, NAD+ infusions were linked to improved pain medicine use.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseAnalgesic use
    Study

    n = 1

    Outcome group
    Pain · Musculoskeletal
    Studied dose
    250 mg · intravenous · four infusions every 2 weeksAs given in this study (human).

    Source sentences

    Summary
    She reported rapid pain relief after individual infusions and subsequent improvement in swelling, morning mobility, function, and analgesic use.
    2 context sentences
    Summary · context
    A 49-year-old woman with a rheumatologist-documented diagnosis of RA had progressive polyarthralgia, intermittent swelling, marked morning stiffness, and baseline hand and wrist ultrasonography showing active synovitis.
    Summary · context
    After approximately 4 months of inconsistently taken methotrexate, discontinued because of adverse effects, she received four intravenous NAD+ infusions for aesthetic and antiaging purposes: 250 mg in 500 mL of 0.9% sodium chloride over approximately 1 hour every 2 weeks.
  6. 06HumanCase report or seriesSafety outcome

    In a woman with rheumatoid arthritis receiving intravenous NAD+, no infusion-related adverse events were reported.

    In plain wordsIn a woman with rheumatoid arthritis receiving NAD+ infusions, no infusion-related side effects were reported.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    Not applicableInfusion-related adverse events
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    250 mg · intravenous · four infusions every 2 weeksAs given in this study (human).

    Source sentences

    Summary
    No infusion-related adverse events were reported.
    2 context sentences
    Summary · context
    A 49-year-old woman with a rheumatologist-documented diagnosis of RA had progressive polyarthralgia, intermittent swelling, marked morning stiffness, and baseline hand and wrist ultrasonography showing active synovitis.
    Summary · context
    After approximately 4 months of inconsistently taken methotrexate, discontinued because of adverse effects, she received four intravenous NAD+ infusions for aesthetic and antiaging purposes: 250 mg in 500 mL of 0.9% sodium chloride over approximately 1 hour every 2 weeks.
  7. 07HumanCase report or seriesEfficacy outcome

    In a woman with rheumatoid arthritis, follow-up ultrasound showed no synovitis after intravenous NAD+ therapy.

    In plain wordsIn a woman with rheumatoid arthritis, no synovitis appeared on follow-up ultrasound after NAD+ infusions.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseSynovitis
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    250 mg · intravenous · four infusions every 2 weeksAs given in this study (human).

    Source sentences

    Summary
    Nine months later, follow-up ultrasonography showed no synovitis or Doppler hyperemia.
    2 context sentences
    Summary · context
    A 49-year-old woman with a rheumatologist-documented diagnosis of RA had progressive polyarthralgia, intermittent swelling, marked morning stiffness, and baseline hand and wrist ultrasonography showing active synovitis.
    Summary · context
    After approximately 4 months of inconsistently taken methotrexate, discontinued because of adverse effects, she received four intravenous NAD+ infusions for aesthetic and antiaging purposes: 250 mg in 500 mL of 0.9% sodium chloride over approximately 1 hour every 2 weeks.
  8. 08HumanCase report or seriesEfficacy outcome

    In a woman with rheumatoid arthritis, follow-up ultrasound showed no Doppler hyperemia after intravenous NAD+ therapy.

    In plain wordsIn a woman with rheumatoid arthritis, no Doppler hyperemia appeared on follow-up ultrasound after NAD+ infusions.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    Direction not reportedDoppler hyperemia
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    250 mg · intravenous · four infusions every 2 weeksAs given in this study (human).

    Source sentences

    Summary
    Nine months later, follow-up ultrasonography showed no synovitis or Doppler hyperemia.
    2 context sentences
    Summary · context
    A 49-year-old woman with a rheumatologist-documented diagnosis of RA had progressive polyarthralgia, intermittent swelling, marked morning stiffness, and baseline hand and wrist ultrasonography showing active synovitis.
    Summary · context
    After approximately 4 months of inconsistently taken methotrexate, discontinued because of adverse effects, she received four intravenous NAD+ infusions for aesthetic and antiaging purposes: 250 mg in 500 mL of 0.9% sodium chloride over approximately 1 hour every 2 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.